Scholar Rock Holding Stock
€7.65
Your prediction
Description Scholar Rock
Scholar Rock is a publicly listed biotechnology company that focuses on developing medicines for patients suffering from serious diseases. Its symbol on the stock market is SRRK. The company is based in Massachusetts, USA, and was founded in 2012. Scholar Rock’s research focuses on discovering and developing drugs that target molecular mechanisms that enable the body to heal itself. It has developed a platform technology that targets a group of proteins known as growth factors, which play a key role in cell signaling and tissue repair. Scholar Rock’s lead drug candidate is SRK-015, which is currently being studied for the treatment of spinal muscular atrophy (SMA), a rare and devastating genetic disease that affects the muscles used for movement. The company has several other drug candidates in pre-clinical development, focusing on areas such as cancer, fibrosis, and neurodegenerative diseases.
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Scholar Rock
sharewise wants to provide you with the best news and tools for Scholar Rock, so we directly link to the best financial data sources.
Financials
News
Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious
Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious
Scholar Rock to Participate in Upcoming Investor Conferences
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious
Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious
Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious
Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious
Scholar Rock to Participate in Upcoming Investor Conferences
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious
Scholar Rock to Host Investor Day on May 22, 2024
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious
Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious